Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

被引：11

作者：

Olszewski, Adam J. ^{[1
]}

Eradat, Herbert ^{[2
]}

Avigdor, Abraham ^{[3
,4
]}

Horowitz, Netanel A. ^{[5
]}

Babu, Sunil ^{[6
]}

Levi, Itai ^{[7
]}

McKinney, Matthew ^{[8
]}

Lee, Seung Tae ^{[9
]}

Bergua Burgues, Juan Miguel ^{[10
]}

Rodriguez Izquierdo, Antonia ^{[11
]}

Bastos-Oreiro, Mariana ^{[12
]}

Ganzel, Chezi ^{[13
,14
]}

Kim, Tae Min ^{[15
]}

Jeon, Youngwoo ^{[16
]}

Taszner, Michal ^{[17
]}

Narkhede, Mayur ^{[18
]}

Kim, Won Seog ^{[19
]}

Shin, Ho-Jin ^{[20
]}

Lavie, David ^{[21
]}

Woszczyk, Dariusz ^{[22
]}

Dunshee, Diana ^{[23
]}

Kapp, Amy V. ^{[23
]}

Zhou, Mingzhu ^{[24
]}

Batlevi, Connie Lee ^{[23
]}

Ead, Wahib ^{[23
]}

Sellam, Gila ^{[25
]}

Jurczak, Wojciech ^{[26
]}

机构：

[1] Brown Univ, Providence, RI USA

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Sheba Med Ctr, Ramat Gan, Israel

[4] Tel Aviv Univ, Sch Med, Tel Aviv, Israel

[5] Technion, Rambam Hlth Care Campus, Haifa, Israel

[6] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA

[7] Soroka Univ Med Ctr, Beer Sheva, Israel

[8] Duke Canc Inst, Durham, NC USA

[9] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA

[10] San Pedro Alcantara Hosp, Hematol & Hemotherapy Serv, Caceres, Spain

[11] Univ Hosp October, Madrid, Spain

[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[13] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[14] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[15] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[16] Yeouido St Marys Hosp, Lymphoma & Cell Therapy Res Ctr, Seoul, South Korea

[17] Med Univ Gdansk, Univ Clin Ctr, Dept Hematol & Transplantol, Gdansk, Poland

[18] Univ Alabama Birmingham, Birmingham, AL USA

[19] Sungkyunkwan Univ, Sch Med, Seoul, South Korea

[20] Pusan Natl Univ, Pusan Natl Univ Hosp, Biochem Res Inst,Sch Med, Dept Internal Med,Div Hematol Oncol, Busan, South Korea

[21] Hadassah Med Ctr, Jerusalem, Israel

[22] Univ Opole, Prov Hosp, Opole, Poland

[23] Genentech Inc, San Francisco, CA USA

[24] F Hoffmann La Roche Ltd, Shanghai, Peoples R China

[25] F Hoffmann La Roche Ltd, Basel, Switzerland

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177588

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[31] Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S461 - S461
[32] Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma
Hanno M. Witte
Armin Riecke
Thomas Mayer
Tobias Bartscht
Dirk Rades
Hendrik Lehnert
Hartmut Merz
Sebastian Fetscher
Harald Biersack
Niklas Gebauer
Journal of Cancer Research and Clinical Oncology, 2019, 145 : 129 - 136
[33] Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma
Witte, Hanno M.
Riecke, Armin
Mayer, Thomas
Bartscht, Tobias
Rades, Dirk
Lehnert, Hendrik
Merz, Hartmut
Fetscher, Sebastian
Biersack, Harald
Gebauer, Niklas
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (01) : 129 - 136
[34] Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Steroids (PolaRCHP) in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Real-Life Experience in Greece
Vassilakopoulos, Theodoros P.
Arapaki, Maria Panagiota
Apostolopoulou, Christina
Kaiafa, Georgia
Mpanti, Anastasia
Giatra, Chara
Verrou, Evgenia
Ioakeim, Maria Anastasia
Triantafyllou, Evangelia Fedra
Makris, Michael-Evangelos
Anastasiadis, Athanasios
Piperidou, Alexia
Liaskas, Athanasios
Delatola, Maria
Koutsi, Aikaterini
Xanthopoulos, Vasileios
Sachanas, Sotirios
Katodrytou, Eirini
Bouzani, Maria
Siakantaris, Marina
Panayiotidis, Panayiotis
Angelopoulou, Maria
Papageorgiou, Sotirios G.
BLOOD, 2024, 144 : 7768 - 7768
[35] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA
Bai, X.
Shao, R.
Zhen, B.
Xia, Y.
He, X.
VALUE IN HEALTH, 2023, 26 (12) : S189 - S189
[36] Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
Mizuoka, Takashi
Sakamaki, Hiroyuki
Fuji, Shigeo
Saito, Shota
Murata, Tatsunori
Ohno, Shinya
Inubashiri, Naoki
Oshima, Tomoha
Yamamoto, Kazuhito
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1122 - 1133
[37] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel, Kishan K.
Isufi, Iris
Kothari, Shalin
Foss, Francine
Huntington, Scott
LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
[38] The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
Kawasaki, Natsumi
Nishito, Yukari
Yoshimura, Yasushi
Yoshiura, Shigeki
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 245 - 255
[39] Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
Younes, Anas
Burke, John M.
Cheson, Bruce D.
Diefenbach, Catherine S.
Ferrari, Silvia
Hahn, Uwe H.
Hawkes, Eliza A.
Khan, Cyrus
Lossos, Izidore S.
Musuraca, Gerardo
Tani, Monica
Vitolo, Umberto
Yuen, Sam
Raval, Aparna
Shivhare, Mahesh
Nielsen, Tina G.
Sellam, Gila
Sharman, Jeff P.
BLOOD ADVANCES, 2023, 7 (08) : 1488 - 1495
[40] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Shi, Yuanfei
Xu, Yi
Wang, Jinghan
Zheng, Xiaolong
Li, Xueying
Jin, Jie
Tong, Hongyan
Xie, Wanzhuo
BLOOD, 2023, 142

← 1 2 3 4 5 →